Radicava Sales Uptake Key to Maintaining Flat Top-Line Over the Next 3-5 Years
We reiterate our “Equal-weight” rating on the stock after reviewing our model post FY17 (YE Mar-18) earningsDomestic pharma, contributing >70%...
1k Views
Mitsubishi Tanabe FY17 Earnings - First Glance
Mitsubishi Tanabe Pharma (4508 JP) reported FY17 results on May, 09 2018 Brisk uptake of recently launched Radicava in the US drove FY17 top-line...
222 Views
Mitsubishi Tanabe (4508) - Acquisition of NeuroDerm Playing to Strength, Not Weakness
The history of overseas acquisitions by Japanese drug companies is not a pretty one, as they've either overpaid for a skillset (Takeda (4502 JP)...
355 Views
Update on Astellas (4503) As It Gets Orphan Drug Status for Gilteritinib
News that gilteritinib has received orphan drug status for acute myeloid leukaemia (AML) would be rather more exciting for Astellas (4503 JP) but...
347 Views
Neurocrine Biosciences: An Attractive Takeover Candidate with Potential >50% Upside.
FDA has accepted the New Drug Application (NDA) for Neurocrine Biosciences Inc (NBIX US) Valbenazine for the treatment of Tardive Dyskinesia (with...
576 Views